Xywav

Not to be confused with Xyrem.

Xywav
Combination of
Calcium oxybateCentral nervous system depressant
Magnesium oxybateCentral nervous system depressant
Potassium oxybateCentral nervous system depressant
Sodium oxybateCentral nervous system depressant
Clinical data
Trade namesXywav
Other namesJZP-258
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa621001
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Xywav is a medication used to treat cataplexy or excessive daytime sleepiness.[2][3] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.[2] It is a central nervous system (CNS) depressant and it is taken by mouth.[2]

Manufactured by the Jazz Pharmaceuticals company, it was approved for medical use in the United States in July 2020.[2][4][5]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ a b c d e "Xywav - calcium, magnesium, potassium, and sodium oxybates solution". DailyMed. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
  3. ^ Halter MJ, Fratena CA (November 2021). "Sleep-Wake Medications". Varcarolis' Manual of Psychiatric Nursing Care. Elsevier Health Sciences. p. 398. ISBN 978-0-323-79306-3. Archived from the original on 20 June 2022. Retrieved 23 December 2021.
  4. ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
  5. ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 27 December 2021. Retrieved 19 November 2021.